This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Grossbard, M. L. Search for Related Content PubMed PubMed Citation Articles by Grossbard, M. L.

Hematologic Malignancies: Selected Abstracts and Commentary

Division of Hematology/Oncology, St. Luke's-Roosevelt Hospital Center, New York, New York, USA

Correspondence: Michael L. Grossbard, M.D., Division of Hematology/Oncology, St. Luke's-Roosevelt Hospital Center, 425 West 59th Street, Suite 1A, New York, New York 10019, USA. Telephone: 212-523-5419; Fax: 212-523-2004; e-mail: mgrossbard{at}slrhc.org

ASCO 2000 did not offer revolutionary new advances in the treatment of hematologic malignancies. However, reports at the meeting built incrementally on gains established over the past several years. The meeting continued to highlight advances in the targeted therapy of hematologic malignancies. Excitement abounds regarding the clinical development of STI 571, a rationally designed tyrosine kinase inhibitor, for the treatment of chronic myelogenous leukemia. Studies further defined the role monoclonal antibody treatment for non-Hodgkin's lymphoma and more mature data were presented on both unconjugated antibody therapy and radioimmunoconjugates. In disease detection, important data were presented to clarify the role of positron emission tomography scans in the staging and follow-up of lymphoid malignancies. The following review summarizes key abstracts presented at the 2000 ASCO meeting and will elaborate on the implications of these findings for disease management.

Key Words. Hematologic malignancies • Positron emission tomography • non-Hodgkin's lymphoma • Follicular lymphoma • I-131 tositumomab